Insulin spending topped $22bn in 2022 and its costs have tripled in the last decade, with major producers following last year’s Inflation Reduction Act and setting a $35 cap on out-of-pocket expenditure. Despite big three firms dominating the market with cheaper versions of branded products, new alternatives are emerging, such as Civica Rx, a nonprofit planning $30 per-vial insulin by 2024, and the state-run CalRx scheme that’s focusing first on insulin.
United States Charges Developer of LockBit Ransomware Group
Rostislav Panev, a 51-year-old dual Russian-Israeli national, has been extradited to the U.S. for his role as a developer in the LockBit ransomware group. Arrested
